CHEK2 and neoplasm: Plasma genotyping will identify gCHEK2m at AF ~50% as shown in Figure 2A while tumor genotpying the AF of gCHEK2m could vary widely though a high AF should alert clinicians to the potential presence of gCHEK2m. One of the limitations of this study is that not many patients with NSCLC undergo plasma NGS genomic profiling, not all plasma NGS genomic profiling assays include CHEK2, and not all NGS assays sequence the whole CHEK2 gene.